Silver Book Fact

Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.

Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Managed Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11925682&dopt=AbstractPlus

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Managed Care Interface
Publication Date
2002
Authors
Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.  
  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $8 billion in 2020–from the…  
  • “A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans…  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…  
  • Medicare Costs, 5-Year Delayed Onset